Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech

Impact · against what's priced in

The deal is a catalyst for Metis TechBio due to the scale of the agreement relative to its size, but it is largely noise for Eli Lilly. For Lilly, the acquisition of drug delivery tech is a tactical pipeline addition that doesn't meaningfully shift the needle on its primary growth drivers or the high valuation the market already supports.

LLY+0.10: Challenges what's priced in
The price assumes: The next-generation pipeline, specifically retatrutide's potential for superior weight loss, which is unpriced
By securing advanced drug delivery technology, Lilly strengthens its ability to defend market share and enhance its next-gen pipeline, a category the market currently ignores.
What LLY's price assumes · Sep 10

Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech

biotech▲14%
healthcare
LLY
drug delivery
partnership
pharma

Top 1 mover · tap to explore

Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech

What matters in this story

How each ticker is affected

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech

What matters in this story

How each ticker is affected

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

Connected tickers

Track these names every morning.

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

Gilead's pill succeeds in mid-stage bowel disease trial

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Kaplan Fox Reminds Investors of a Securities Class Action Against Ardelyx, Inc. (ARDX) - Deadline is November 16, 2026

Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech

What matters in this story

How each ticker is affected

Next reads from the same story arc

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

Metis TechBio inks up to $1.1 billion deal with Eli Lilly for drug delivery tech

What matters in this story

How each ticker is affected

Next reads from the same story arc

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

Connected tickers

Track these names every morning.

Marvel Biosciences Advances MB-204 Toward First-in Human Testing, Selects CMAX as Phase I Clinical Trial Site

Gilead's pill succeeds in mid-stage bowel disease trial

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Kaplan Fox Reminds Investors of a Securities Class Action Against Ardelyx, Inc. (ARDX) - Deadline is November 16, 2026